Pfizer reported $63.7B of revenue over the trailing twelve months, −0.21% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $63.7B (to Q2 2026). Net Income: $4.33B, trailing twelve months to Q2 2026. Free Cash Flow: $11.0B, trailing twelve months to Q2 2026. EPS: $0.76, trailing twelve months to Q2 2026.

PFEPfizer

HealthcareUSD

$28.32

$22.4452 weeks$28.57

PFE as reported

Pfizer reported $63.7B of revenue over the trailing twelve months, −0.21% on the year before. 9 reported series are charted on this page, each one as filed.

$63.7B

Revenue, trailing twelve months · to Q2 2026 · −0.21% against the twelve months before

Net Income: $4.33B
Net Income · −60% year on year · trailing twelve months to Q2 2026
Free Cash Flow: $11.0B
Free Cash Flow · −12% year on year · trailing twelve months to Q2 2026
EPS: $0.76
EPS · −60% year on year · trailing twelve months to Q2 2026

Every series Ryufin has for PFE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$63.7B	−0.21%	Q2 2026
Net Income	$4.33B	−60%	Q2 2026
EPS	$0.76	−60%	Q2 2026
Gross Margin	73%	n/a	Q2 2026
Net Margin	7.2%	n/a	Q2 2026
ROE	8.2%	n/a	Q2 2026
ROA	3.6%	n/a	Q2 2026
Free Cash Flow	$11.0B	−12%	Q2 2026
P/E	37.3	n/a	today